Peripheral T-Cell Lymphoma - Epidemiology Forecast - 2032

This Peripheral T-cell Lymphoma - Epidemiology Forecast- 2032” report delivers an in-depth understanding of the PTCL, historical and forecasted epidemiology as well as the PTCL market trends in the United States, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Geography Covered

• The United States
• The EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Peripheral T-cell Lymphoma Disease Understanding and Treatment Algorithm

Peripheral T-cell Lymphoma Overview

Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of clinically aggressive types of non-Hodgkin lymphoma (NHL) that develop in mature white blood cells called “T cells” and “natural killer (NK) cells.” It is PTCL's origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term “peripheral” does not refer to the extremities, but identifies PTCL as cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.

Signs and symptoms of PTCL include asymptomatic lymphadenopathy, Fever, night sweats, poor appetite, and weight loss include fatigue, painless swelling in the neck, armpit or groin (due to an enlarged lymph node). Different staging systems have been proposed for PTCLs.

Peripheral T-cell Lymphoma Diagnosis

The cells in many subtypes of PTCLs look alike; therefore, making an accurate diagnosis may require the use of additional diagnostic tests, including blood tests, CT (computerized axial tomography), PET (positron emission tomography) scans, MRI (magnetic resonance imaging), and bone marrow biopsy.

Peripheral T-cell Lymphoma Treatment

Currently, newly diagnosed PTCL patients are usually treated with anthracycline-based chemotherapy regimens. For most subtypes of PTCL, the initial treatment is typically a combination chemotherapy regimen, such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone), or other multidrug regimens. Patients with relapsed disease are usually treated with combination chemotherapy such as ICE (ifosfamide, carboplatin, and etoposide) or other combination regimens, followed by stem cell transplantation. Treatment for PTCL aims to cure and includes the use of combination chemotherapy regimens - typically CHOP based chemotherapy or EPOCH, localized radiotherapy, stem cell transplants and steroid therapy. Other drugs now approved for relapsed T-cell lymphoma include BELEODAQ (belinostat), ADCETRIS (brentuximab vedotin), POTELIGEO (mogamulizumab), Mundesine (Forodesine Hydrochloride), HIYASTA, DARVIAS, and Others.

Peripheral T-cell Lymphoma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of PTCL, stage-specific Incident Cases of PTCL, and subtype-specific Incident cases of PTCL in the 7MM market covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the PTCL epidemiology in the 7MM

Country Wise- Peripheral T-cell Lymphoma Epidemiology

• The epidemiology segment also provides the PTCL epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The total incident population of PTCL in the 7MM comprised of 18,027 cases in 2021 and are projected to increase during the forecast period.
• The total incident population of PTCL in the United States is 6,366 in 2021.
• The Japan contributed to the largest incident population of PTCL, accounting for ~ 37% of the 7MM in 2021.
• Among the EU-5 countries, Germany accounted for the highest number of PTCL cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
• In Japan, the total incident population of PTCL was 6,637 in 2021 and is anticipated to rise during the forecast period.
• The major types of PTCL include Peripheral T-cell lymphoma (NOS), Anaplastic Large-Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL) and others. In 2021, the incident population of NOS, ALCL, and AITL in the United States were, 1,998, 1,643, and 1,438, cases.

Scope of the Report

• The report covers the descriptive overview of PTCL, explaining its causes, signs and symptoms, pathogenesis and diagnosis.
• Comprehensive insight has been provided into the PTCL epidemiology and treatment.
• The report provides insight about the historical and forecasted patient pool of PTCL in seven major markets covering the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• A detailed review of PTCL epidemiology forecast is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding epidemiological trends.

Report Highlights

• In the coming years, PTCL market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence PTCL R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• As per the analysis the major types of PTCL include Peripheral T-cell lymphoma-NOS, Anaplastic Large-Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL), Nasal NK/T-cell lymphoma, Enteropathy-type intestinal TCL, Hepatosplenic TCL and others.
• The report also encompasses other major segments, i.e. total incident population of PTCL, stage-specific Incident Cases of PTCL, and subtype-specific Incident cases of PTCL.

PTCL Report Insights

PTCL Report Insights

• Patient Population
• Eleven Years Forecast
• 7MM Coverage
• PTCL Epidemiology Segmentation

Key Questions Answered

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of PTCL?
• What is the historical PTCL patient pool in the United States, the EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of PTCL at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to PTCL?
• Out of the above-mentioned countries, which country would have the highest incident population of PTCL during the study period (2019-2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the PTCL.
• To understand the future market competition in the PTCL market and Insightful review of the SWOT analysis of PTCL.
• Organize sales and marketing efforts by identifying the best opportunities for PTCL in the US, the EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for PTCL market.
• To understand the future market competition in the PTCL market.